MX368210B - Composiciones que comprenden bacterias y usos de las mismas en el tratamiento del cáncer. - Google Patents
Composiciones que comprenden bacterias y usos de las mismas en el tratamiento del cáncer.Info
- Publication number
- MX368210B MX368210B MX2015008606A MX2015008606A MX368210B MX 368210 B MX368210 B MX 368210B MX 2015008606 A MX2015008606 A MX 2015008606A MX 2015008606 A MX2015008606 A MX 2015008606A MX 368210 B MX368210 B MX 368210B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- methods
- bacteria
- pyrogenicity
- gram
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- 241000894006 Bacteria Species 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000007893 endotoxin activity Effects 0.000 abstract 3
- 239000002510 pyrogen Substances 0.000 abstract 3
- 230000001580 bacterial effect Effects 0.000 abstract 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 108010040201 Polymyxins Proteins 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 230000009395 genetic defect Effects 0.000 abstract 1
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a composiciones que comprenden sustancialmente organismos bacterianos Gramnegativos no viables que tienen una reducción sustancial en la actividad y/o pirogenicidad de endotoxina y métodos para tratar un cáncer usando los mismos. También se proporcionan métodos para tratar cáncer proporcionados en la presente, que comprenden administrar a un mamífero diagnosticado con cáncer, bacterias Gram-negativas sustancialmente no viables que tienen una reducción sustancial en la actividad y/o pirogenicidad de endotoxina en una cantidad suficiente para inhibir el crecimiento o metástasis del cáncer. Se proporciona un método adicional que comprende administrar organismos bacterianos Gram-negativos viables o no viables que tienen un defecto genético que da por resultado una pérdida sustancial de lipopolisacárido dentro de la membrana exterior de las bacterias. Se proporciona adicionalmente métodos para reducir la actividad y/o pirogenicidad de endotoxina en bacterias Gram-negativas, que comprenden el tratamiento con polimixina y glutaraldehído.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361748369P | 2013-01-02 | 2013-01-02 | |
PCT/US2013/077441 WO2014107365A1 (en) | 2013-01-02 | 2013-12-23 | Compositions and methods for treatment of cancer using bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015008606A MX2015008606A (es) | 2016-01-14 |
MX368210B true MX368210B (es) | 2019-09-24 |
Family
ID=49943600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008606A MX368210B (es) | 2013-01-02 | 2013-12-23 | Composiciones que comprenden bacterias y usos de las mismas en el tratamiento del cáncer. |
Country Status (17)
Country | Link |
---|---|
US (5) | US9265804B2 (es) |
EP (1) | EP2941258B1 (es) |
JP (1) | JP6125041B2 (es) |
KR (1) | KR102214794B1 (es) |
CN (1) | CN104884073B (es) |
AU (1) | AU2013371454B2 (es) |
CA (1) | CA2896858C (es) |
DK (1) | DK2941258T3 (es) |
EA (1) | EA030573B1 (es) |
ES (1) | ES2759854T3 (es) |
HK (1) | HK1217289A1 (es) |
IL (1) | IL239453B (es) |
MX (1) | MX368210B (es) |
PL (1) | PL2941258T3 (es) |
PT (1) | PT2941258T (es) |
TW (1) | TWI664976B (es) |
WO (1) | WO2014107365A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA030573B1 (ru) * | 2013-01-02 | 2018-08-31 | Дикой Байосистемз, Инк. | Композиции и способы для лечения рака с применением бактерий |
US20150283237A1 (en) * | 2014-04-02 | 2015-10-08 | Mitchell S. Felder | Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer |
JP6629211B2 (ja) * | 2014-08-19 | 2020-01-15 | 国立大学法人 岡山大学 | 免疫細胞の機能増強方法及び免疫細胞の多機能性評価方法 |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US20200282037A1 (en) * | 2017-06-16 | 2020-09-10 | Nantbio, Inc. | Bacterial vaccine |
US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
DK3713586T3 (da) | 2017-11-20 | 2023-03-27 | Codex Dna Inc | Vibrio sp. organismer med modificeret lipopolysaccharid |
CA3088343A1 (en) * | 2018-01-19 | 2019-07-25 | 4D Pharma Research Limited | Combination therapy for treating or preventing cancer |
KR20210030973A (ko) | 2018-07-11 | 2021-03-18 | 액팀 테라퓨틱스, 인코퍼레이티드 | 조작된 면역자극성 박테리아 균주 및 이의 용도 |
US11242528B2 (en) | 2018-08-28 | 2022-02-08 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
US11147844B2 (en) | 2018-09-27 | 2021-10-19 | Decoy Biosystems, Inc. | Methods of treatment of infections using bacteria |
US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
WO2020232389A1 (en) * | 2019-05-16 | 2020-11-19 | City Of Hope | Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery |
US20220296625A1 (en) * | 2019-08-29 | 2022-09-22 | Biomedical Research Group Inc. | Cancer chemotherapy supporting agent, food, and drug |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
JP2023548417A (ja) * | 2020-11-09 | 2023-11-16 | インダストリー、ファウンデーション、オブ、チョンナム、ナショナル、ユニバーシティ | 癌の予防および治療用サルモネラ菌株およびその用途 |
FI129784B (en) * | 2021-04-27 | 2022-08-31 | Solar Foods Oy | METHODS OF PRODUCING MICROPRODUCTS |
US20240075123A1 (en) * | 2022-11-17 | 2024-03-07 | Indaptus Therapeutics, Inc. | Treatment of cancers and infectious diseases with killed intact bacteria |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4842855A (en) * | 1980-12-19 | 1989-06-27 | University Of Pittsburgh | Antitumor process using a Brucella abortus preparation |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US5171738A (en) | 1982-10-04 | 1992-12-15 | Toray Industries, Inc. | Method of treating malignant tumors |
JPH04270965A (ja) * | 1990-05-18 | 1992-09-28 | Burton W Blais | オリゴペプタイド吸着担体の調製方法、及びこれを使用したリポ多糖類の検定と除去方法 |
US6264952B1 (en) | 1993-11-05 | 2001-07-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for protecting a mammalian host against infection by Brucella |
WO1996030043A1 (en) | 1995-03-24 | 1996-10-03 | Ophidian Pharmaceuticals | Treatment for verotoxin-producing escherichia coli |
US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5997881A (en) * | 1995-11-22 | 1999-12-07 | University Of Maryland, Baltimore | Method of making non-pyrogenic lipopolysaccharide or A |
AU7701098A (en) | 1997-05-28 | 1998-12-30 | Michael A. Apicella | Laft mutants of pathogenic gram-negative bacteria |
IL134936A0 (en) | 1997-09-10 | 2001-05-20 | Vion Pharmaceuticals Inc | Genetically modified tumor-targeted bacteria with reduced virulence |
MXPA02003384A (es) * | 1999-10-04 | 2002-08-20 | Vion Pharmaceuticals Inc | Composiciones y metodos para atacar tumores y entrega de moleculas determinantes. |
WO2001024637A1 (en) * | 1999-10-04 | 2001-04-12 | Vion Pharmaceuticals, Inc. | Methods for treating solid tumors with irradiation and bacteria |
US6962696B1 (en) * | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
ATE419880T1 (de) * | 2000-06-09 | 2009-01-15 | Baylor College Medicine | Kombination von antimikrobiellen wirkstoffen und bakterieller interferenz zum überziehen medizinischer vorrichtungen |
US7344710B2 (en) | 2001-11-21 | 2008-03-18 | The Johns Hopkins University | Combination bacteriolytic therapy for the treatment of tumors |
WO2003063593A1 (en) | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
ATE459364T1 (de) | 2003-10-22 | 2010-03-15 | Univ Johns Hopkins | Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren |
PL1765391T3 (pl) | 2004-06-07 | 2013-08-30 | Qu Biologics Inc | Kompozycje bakteryjne do leczenia nowotworów |
US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
US8034359B2 (en) | 2004-06-07 | 2011-10-11 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to cancers |
AU2005260697B2 (en) | 2004-06-29 | 2011-10-06 | Anticancer, Inc. | Cancer selective auxotrophs |
ES2589314T3 (es) | 2006-01-19 | 2016-11-11 | Research Corporation Technologies, Inc. | Bacterias Gram-negativas viables no tóxicas |
EP2545162B1 (en) | 2010-03-12 | 2016-10-19 | Research Corporation Technologies | Viable gram negative bacteria lacking outer membrane agonists of tlr4/md-2 |
EA030573B1 (ru) | 2013-01-02 | 2018-08-31 | Дикой Байосистемз, Инк. | Композиции и способы для лечения рака с применением бактерий |
-
2013
- 2013-12-23 EA EA201591017A patent/EA030573B1/ru not_active IP Right Cessation
- 2013-12-23 CA CA2896858A patent/CA2896858C/en active Active
- 2013-12-23 JP JP2015550723A patent/JP6125041B2/ja active Active
- 2013-12-23 ES ES13818965T patent/ES2759854T3/es active Active
- 2013-12-23 WO PCT/US2013/077441 patent/WO2014107365A1/en active Application Filing
- 2013-12-23 US US14/139,063 patent/US9265804B2/en active Active
- 2013-12-23 EP EP13818965.9A patent/EP2941258B1/en active Active
- 2013-12-23 AU AU2013371454A patent/AU2013371454B2/en active Active
- 2013-12-23 TW TW102147759A patent/TWI664976B/zh active
- 2013-12-23 CN CN201380069002.XA patent/CN104884073B/zh active Active
- 2013-12-23 DK DK13818965.9T patent/DK2941258T3/da active
- 2013-12-23 KR KR1020157020243A patent/KR102214794B1/ko active IP Right Grant
- 2013-12-23 PL PL13818965T patent/PL2941258T3/pl unknown
- 2013-12-23 MX MX2015008606A patent/MX368210B/es active IP Right Grant
- 2013-12-23 PT PT138189659T patent/PT2941258T/pt unknown
- 2013-12-23 US US14/377,693 patent/US10195259B2/en active Active
-
2015
- 2015-06-16 IL IL239453A patent/IL239453B/en active IP Right Grant
-
2016
- 2016-01-21 US US15/003,726 patent/US10052371B2/en active Active
- 2016-05-09 HK HK16105240.9A patent/HK1217289A1/zh unknown
-
2019
- 2019-01-04 US US16/240,217 patent/US11045504B2/en active Active
-
2021
- 2021-06-25 US US17/359,375 patent/US20220047649A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015008606A (es) | Composiciones y metodos para tratamiento de cancer usando bacterias. | |
PH12016502148A1 (en) | Methods of microalgae cultivation for increased resource production | |
MX2021001859A (es) | Medio de cultivo celular libre de suero. | |
AU2011372711B2 (en) | Method for processing mesenchymal stem cells and the use thereof in the treatment of diseases associated with oxidative stress | |
MX2019007143A (es) | Procesamiento de materiales de biomasa. | |
MX355741B (es) | Metodos y composiciones de fermentacion microbiana. | |
EP3284816A4 (en) | Culture medium additive, culture medium composition, and method for culturing cells or tissue using same | |
MX361324B (es) | Metodo de enriquecimiento proteico de la biomasa de microalgas. | |
WO2014127351A3 (en) | Compositions and methods to alter gut microbial fermentation using sulfate-reducing bacteria | |
EP3205713A4 (en) | Method for culturing 1,4-dioxane-decomposing bacteria, culture medium, and 1,4-dioxane treatment method using 1,4-dioxane-decomposing bacteria | |
MX2016005824A (es) | Metodo de cultivo celular. | |
MX2017002234A (es) | Metodos de cultivo semicontinuo. | |
MX2013007053A (es) | Uso de compuestos que libera peroxigeno libre de nitrogeno para reducir el crecimiento de microorganismos contaminates en la fermentacion de etanol. | |
MX2022001428A (es) | Metodos y composiciones para cultivar bacterias dependientes de hemoglobina. | |
PL386175A1 (pl) | Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych rodzaju Enterococcus | |
MX2021014202A (es) | Metodos y composiciones para la fermentacion bacteriana anaerobia. | |
EP2491142A4 (en) | GENERATING AN IMMUNE RESPONSE TO REDUCE THE RISK OF DEVELOPING BRUCELLOSIS | |
MX2017002150A (es) | Metodos de cultivo por lotes alimentados con repeticion. | |
MX2016013363A (es) | Metodo para aumentar la capacidad de sintesis de biomasa de microorganismos y microorganismos modificados a partir de ellos. | |
MX2016008595A (es) | Expresion mejorada de proteínas. | |
PL419275A1 (pl) | Haloizyt do stosowania jako dodatek paszowy oraz sposób zwiększania wzrostu, żywotności i wydajności drobiu | |
UA86029U (ru) | Способ определения антимикробной активности дезинфекционных средств | |
PL410460A1 (pl) | Biopreparat do konserwowania surowców odnawialnych przeznaczonych do produkcji biogazu | |
PH12021550013A1 (en) | Method for producing protein | |
UA93704C2 (ru) | Способ получения биомассы бактерий для бактериесодержащих препаратов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |